Loading…

Exploring the experience of developing COVID-19 vaccines in Iran

Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructur...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and experimental vaccine research (Seoul) 2023, 12(1), , pp.1-12
Main Authors:	Ghanei, Mostafa, Mohabattalab, Ali, Fartash, Kiarash, Kolahchi, Narjes, Khakdaman, Alireza, Kaghazian, Hooman, Bagheri, Abolfazl
Format:	Article
Language:	English
Subjects:	Chief executive officers Coronaviruses COVID-19 vaccines Immunization Infectious diseases Pandemics Review 예방의학
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73
cites	cdi_FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73
container_end_page	12
container_issue	1
container_start_page	1
container_title	Clinical and experimental vaccine research (Seoul)
container_volume	12
creator	Ghanei, Mostafa Mohabattalab, Ali Fartash, Kiarash Kolahchi, Narjes Khakdaman, Alireza Kaghazian, Hooman Bagheri, Abolfazl
description	Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies. Due to the global demand for vaccines during the pandemic, the national capability to produce vaccines is critical. To this end, the current paper investigates influential factors, at the firm- and policy-level, in the COVID-19 vaccine development process in Iran. By adopting a qualitative research method and conducting 17 semi-structured interviews and analyzing policy documents, news, and reports, we extracted internal and external factors affecting the success and failure of a vaccine development project. We also discuss the characteristics of the vaccine ecosystem and the gradual maturity of policies. This paper draws lessons for vaccine development in developing countries at both firm and policy levels.
doi_str_mv	10.7774/cevr.2023.12.1.1
format	article
fullrecord	<record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10118426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780484984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYMottS--yQDvogwY74_XsSytrpQKEgV30Ime6dNO5uMye5S__tmd-ui3pcbuL9zuDcHodcEd0op_sHDJncUU9YR2pGOPEPHlGrVMil_Pj-8BTlCp6Xc4VqaSCPIS3TEpOZcanWMPp0_TGPKId40q1to4GGCHCB6aNLQLGADY5q2w9nVj_nnlphm47wPEUoTYjPPLr5CLwY3Fjh96ifo-8X59exre3n1ZT47u2w9F2bVSu6Z1lhopymRrne9JIOhWhitmQTtMRNO9G7gvcBcUUaF13IxKFrL9IqdoPd735gHe--DTS7s-k2y99mefbueW4IJ0ZzKCn_cw9O6X8LCQ1xlN9oph6XLv3fSfycx3FajjTVGYLozePdkkNOvNZSVXYbiYRxdhLQuliqNueZG84q-_Q-9S-sc619USu1OZKZSeE_5nErJMByWIdhu47TbOO02TkuoJZZUyZu_jzgI_oTHHgHmkJkE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779285939</pqid></control><display><type>article</type><title>Exploring the experience of developing COVID-19 vaccines in Iran</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central(OpenAccess)</source><source>Coronavirus Research Database</source><creator>Ghanei, Mostafa ; Mohabattalab, Ali ; Fartash, Kiarash ; Kolahchi, Narjes ; Khakdaman, Alireza ; Kaghazian, Hooman ; Bagheri, Abolfazl</creator><creatorcontrib>Ghanei, Mostafa ; Mohabattalab, Ali ; Fartash, Kiarash ; Kolahchi, Narjes ; Khakdaman, Alireza ; Kaghazian, Hooman ; Bagheri, Abolfazl</creatorcontrib><description>Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies. Due to the global demand for vaccines during the pandemic, the national capability to produce vaccines is critical. To this end, the current paper investigates influential factors, at the firm- and policy-level, in the COVID-19 vaccine development process in Iran. By adopting a qualitative research method and conducting 17 semi-structured interviews and analyzing policy documents, news, and reports, we extracted internal and external factors affecting the success and failure of a vaccine development project. We also discuss the characteristics of the vaccine ecosystem and the gradual maturity of policies. This paper draws lessons for vaccine development in developing countries at both firm and policy levels.</description><identifier>ISSN: 2287-3651</identifier><identifier>EISSN: 2287-366X</identifier><identifier>DOI: 10.7774/cevr.2023.12.1.1</identifier><identifier>PMID: 36844687</identifier><language>eng</language><publisher>Korea (South): Korean Vaccine Society</publisher><subject>Chief executive officers ; Coronaviruses ; COVID-19 vaccines ; Immunization ; Infectious diseases ; Pandemics ; Review ; 예방의학</subject><ispartof>Clinical and Experimental Vaccine Research , 2023, 12(1), , pp.1-12</ispartof><rights>Korean Vaccine Society.</rights><rights>2023. This work is published under https://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Korean Vaccine Society. 2023 Korean Vaccine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73</citedby><cites>FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73</cites><orcidid>0000-0002-0970-3496 ; 0000-0001-9316-3930 ; 0000-0001-9372-0928 ; 0000-0003-1308-4795 ; 0000-0002-2954-906X ; 0000-0003-4301-3381 ; 0000-0003-0883-7588</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2779285939/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2779285939?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,723,776,780,788,881,4010,25731,27899,27900,27901,27902,36989,36990,38493,43871,44566,53766,53768,74382,75096</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36844687$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002930388$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghanei, Mostafa</creatorcontrib><creatorcontrib>Mohabattalab, Ali</creatorcontrib><creatorcontrib>Fartash, Kiarash</creatorcontrib><creatorcontrib>Kolahchi, Narjes</creatorcontrib><creatorcontrib>Khakdaman, Alireza</creatorcontrib><creatorcontrib>Kaghazian, Hooman</creatorcontrib><creatorcontrib>Bagheri, Abolfazl</creatorcontrib><title>Exploring the experience of developing COVID-19 vaccines in Iran</title><title>Clinical and experimental vaccine research (Seoul)</title><addtitle>Clin Exp Vaccine Res</addtitle><description>Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies. Due to the global demand for vaccines during the pandemic, the national capability to produce vaccines is critical. To this end, the current paper investigates influential factors, at the firm- and policy-level, in the COVID-19 vaccine development process in Iran. By adopting a qualitative research method and conducting 17 semi-structured interviews and analyzing policy documents, news, and reports, we extracted internal and external factors affecting the success and failure of a vaccine development project. We also discuss the characteristics of the vaccine ecosystem and the gradual maturity of policies. This paper draws lessons for vaccine development in developing countries at both firm and policy levels.</description><subject>Chief executive officers</subject><subject>Coronaviruses</subject><subject>COVID-19 vaccines</subject><subject>Immunization</subject><subject>Infectious diseases</subject><subject>Pandemics</subject><subject>Review</subject><subject>예방의학</subject><issn>2287-3651</issn><issn>2287-366X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNpdkd1rFDEUxYMottS--yQDvogwY74_XsSytrpQKEgV30Ime6dNO5uMye5S__tmd-ui3pcbuL9zuDcHodcEd0op_sHDJncUU9YR2pGOPEPHlGrVMil_Pj-8BTlCp6Xc4VqaSCPIS3TEpOZcanWMPp0_TGPKId40q1to4GGCHCB6aNLQLGADY5q2w9nVj_nnlphm47wPEUoTYjPPLr5CLwY3Fjh96ifo-8X59exre3n1ZT47u2w9F2bVSu6Z1lhopymRrne9JIOhWhitmQTtMRNO9G7gvcBcUUaF13IxKFrL9IqdoPd735gHe--DTS7s-k2y99mefbueW4IJ0ZzKCn_cw9O6X8LCQ1xlN9oph6XLv3fSfycx3FajjTVGYLozePdkkNOvNZSVXYbiYRxdhLQuliqNueZG84q-_Q-9S-sc619USu1OZKZSeE_5nErJMByWIdhu47TbOO02TkuoJZZUyZu_jzgI_oTHHgHmkJkE</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Ghanei, Mostafa</creator><creator>Mohabattalab, Ali</creator><creator>Fartash, Kiarash</creator><creator>Kolahchi, Narjes</creator><creator>Khakdaman, Alireza</creator><creator>Kaghazian, Hooman</creator><creator>Bagheri, Abolfazl</creator><general>Korean Vaccine Society</general><general>The Korean Vaccine Society</general><general>대한백신학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-0970-3496</orcidid><orcidid>https://orcid.org/0000-0001-9316-3930</orcidid><orcidid>https://orcid.org/0000-0001-9372-0928</orcidid><orcidid>https://orcid.org/0000-0003-1308-4795</orcidid><orcidid>https://orcid.org/0000-0002-2954-906X</orcidid><orcidid>https://orcid.org/0000-0003-4301-3381</orcidid><orcidid>https://orcid.org/0000-0003-0883-7588</orcidid></search><sort><creationdate>202301</creationdate><title>Exploring the experience of developing COVID-19 vaccines in Iran</title><author>Ghanei, Mostafa ; Mohabattalab, Ali ; Fartash, Kiarash ; Kolahchi, Narjes ; Khakdaman, Alireza ; Kaghazian, Hooman ; Bagheri, Abolfazl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Chief executive officers</topic><topic>Coronaviruses</topic><topic>COVID-19 vaccines</topic><topic>Immunization</topic><topic>Infectious diseases</topic><topic>Pandemics</topic><topic>Review</topic><topic>예방의학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghanei, Mostafa</creatorcontrib><creatorcontrib>Mohabattalab, Ali</creatorcontrib><creatorcontrib>Fartash, Kiarash</creatorcontrib><creatorcontrib>Kolahchi, Narjes</creatorcontrib><creatorcontrib>Khakdaman, Alireza</creatorcontrib><creatorcontrib>Kaghazian, Hooman</creatorcontrib><creatorcontrib>Bagheri, Abolfazl</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Clinical and experimental vaccine research (Seoul)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghanei, Mostafa</au><au>Mohabattalab, Ali</au><au>Fartash, Kiarash</au><au>Kolahchi, Narjes</au><au>Khakdaman, Alireza</au><au>Kaghazian, Hooman</au><au>Bagheri, Abolfazl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring the experience of developing COVID-19 vaccines in Iran</atitle><jtitle>Clinical and experimental vaccine research (Seoul)</jtitle><addtitle>Clin Exp Vaccine Res</addtitle><date>2023-01</date><risdate>2023</risdate><volume>12</volume><issue>1</issue><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>2287-3651</issn><eissn>2287-366X</eissn><abstract>Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies. Due to the global demand for vaccines during the pandemic, the national capability to produce vaccines is critical. To this end, the current paper investigates influential factors, at the firm- and policy-level, in the COVID-19 vaccine development process in Iran. By adopting a qualitative research method and conducting 17 semi-structured interviews and analyzing policy documents, news, and reports, we extracted internal and external factors affecting the success and failure of a vaccine development project. We also discuss the characteristics of the vaccine ecosystem and the gradual maturity of policies. This paper draws lessons for vaccine development in developing countries at both firm and policy levels.</abstract><cop>Korea (South)</cop><pub>Korean Vaccine Society</pub><pmid>36844687</pmid><doi>10.7774/cevr.2023.12.1.1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-0970-3496</orcidid><orcidid>https://orcid.org/0000-0001-9316-3930</orcidid><orcidid>https://orcid.org/0000-0001-9372-0928</orcidid><orcidid>https://orcid.org/0000-0003-1308-4795</orcidid><orcidid>https://orcid.org/0000-0002-2954-906X</orcidid><orcidid>https://orcid.org/0000-0003-4301-3381</orcidid><orcidid>https://orcid.org/0000-0003-0883-7588</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2287-3651
ispartof	Clinical and Experimental Vaccine Research , 2023, 12(1), , pp.1-12
issn	2287-3651 2287-366X
language	eng
recordid	cdi_nrf_kci_oai_kci_go_kr_ARTI_10118426
source	Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central(OpenAccess); Coronavirus Research Database
subjects	Chief executive officers Coronaviruses COVID-19 vaccines Immunization Infectious diseases Pandemics Review 예방의학
title	Exploring the experience of developing COVID-19 vaccines in Iran
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T16%3A29%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20the%20experience%20of%20developing%20COVID-19%20vaccines%20in%20Iran&rft.jtitle=Clinical%20and%20experimental%20vaccine%20research%20(Seoul)&rft.au=Ghanei,%20Mostafa&rft.date=2023-01&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=2287-3651&rft.eissn=2287-366X&rft_id=info:doi/10.7774/cevr.2023.12.1.1&rft_dat=%3Cproquest_nrf_k%3E2780484984%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-64c388058a8216abab61f928598836e8c035a5baf4b50472325c86df722229b73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2779285939&rft_id=info:pmid/36844687&rfr_iscdi=true